@article{WiechingBenserKohlhauserVollmuthetal.2012,
  author    = {Wieching, Anna and Benser, Jasmin and Kohlhauser-Vollmuth, Christina and Weisbrich, Bendikt and Streng, Andrea and Liese, Johannes G.},
  title     = {Clinical characteristics of pediatric hospitalizations associated with 2009 pandemic influenza a (H1N1) in Northern Bavaria, Germany},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-75657},
  year      = {2012},
  abstract  = {Background: The 2009 pandemic influenza A (H1N1) (PIA) virus infected large parts of the pediatric population with a wide clinical spectrum and an initially unknown complication rate. The aims of our study were to define clinical characteristics and outcome of pandemic influenza A (H1N1) 2009-associated hospitalizations (PIAH) in children <18 years of age. All hospitalized cases of children <18 years of age with laboratory-confirmed pandemic influenza A (H1N1) 2009 in the region of Wuerzburg (Northern Bavaria, Germany) between July 2009 and March 2010 were identified. For these children a medical chart review was performed to determine their clinical characteristics and complications. Results: Between July 2009 and March 2010, 94 PIAH (62\% males) occurred in children <18 years of age, with a median age of 7 years (IQR: 3-12 years). Underlying diseases and predisposing factors were documented in 40 (43\%) children; obesity (n = 12, 30\%), asthma (n = 10, 25\%) and neurologic disorders (n = 8, 20\%) were most frequently reported. Sixteen (17\%) children received oxygen supplementation; three (3\%) children required mechanical ventilation. Six (6\%) children were admitted to an intensive care unit, four of them with underlying chronic diseases. Conclusions: Most PIAH demonstrated a benign course of disease. However, six children (6\%) needed treatment at an intensive care unit for severe complications.},
  subject      = {Medizin},
  language  = {en}
}
@article{vonKriesWeissFalkenhorstetal.2011,
  author    = {von Kries, R{\"u}diger and Weiss, Susanne and Falkenhorst, Gerhard and Wirth, Stephan and Kaiser, Petra and Huppertz, Hans-Iko and Tenenbaum, Tobias and Schroten, Horst and Streng, Andrea and Liese, Johannes and Shai, Sonu and Niehues, Tim and Girschick, Hermann and Kuscher, Ellen and Sauerbrey, Axel and Peters, Jochen and Wirsing von Koenig, Carl Heinz and R{\"u}ckinger, Simon and Hampl, Walter and Michel, Detlef and Mertens, Thomas},
  title     = {Post-Pandemic Seroprevalence of Pandemic Influenza A (H1N1) 2009 Infection (Swine Flu) among Children < 18 Years in Germany},
  series = {PLoS ONE},
  volume    = {6},
  journal   = {PLoS ONE},
  number    = {9},
  doi       = {10.1371/journal.pone.0023955},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-141698},
  pages     = {e23955},
  year      = {2011},
  abstract  = {Background: We determined antibodies to the pandemic influenza A (H1N1) 2009 virus in children to assess: the incidence of (H1N1) 2009 infections in the 2009/2010 season in Germany, the proportion of subclinical infections and to compare titers in vaccinated and infected children. Methodology/Principal Findings: Eight pediatric hospitals distributed over Germany prospectively provided sera from in-or outpatients aged 1 to 17 years from April 1(st) to July 31(st) 2010. Vaccination history, recall of infections and sociodemographic factors were ascertained. Antibody titers were measured with a sensitive and specific in-house hemagglutination inhibition test (HIT) and compared to age-matched sera collected during 6 months before the onset of the pandemic in Germany. We analyzed 1420 post-pandemic and 300 pre-pandemic sera. Among unvaccinated children aged 1-4 and 5-17 years the prevalence of HI titers (>= 1:10) was 27.1\% (95\% CI: 23.5-31.3) and 53.5\% (95\% CI: 50.9-56.2) compared to 1.7\% and 5.5\%, respectively, for pre-pandemic sera, accounting for a serologically determined incidence of influenza A (H1N1) 2009 during the season 2009/2010 of 25,4\% (95\% CI : 19.3-30.5) in children aged 1-4 years and 48.0\% (95\% CI: 42.6-52.0) in 5-17 year old children. Of children with HI titers >= 1: 10, 25.5\% (95\% CI: 22.5-28.8) reported no history of any infectious disease since June 2009. Among vaccinated children, 92\% (95\%-CI: 87.0-96.6) of the 5-17 year old but only 47.8\% (95\%-CI: 33.5-66.5) of the 1-4 year old children exhibited HI titers against influenza A virus (H1N1) 2009. Conclusion: Serologically determined incidence of influenza A (H1N1) 2009 infections in children indicates high infection rates with older children (5-17 years) infected twice as often as younger children. In about a quarter of the children with HI titers after the season 2009/2010 subclinical infections must be assumed. Low HI titers in young children after vaccination with the AS03(B)-adjuvanted split virion vaccine need further scrutiny.},
  language  = {en}
}
@article{StrengPrifertWeissbrichetal.2022,
  author    = {Streng, Andrea and Prifert, Christiane and Weissbrich, Benedikt and Sauerbrei, Andreas and Krumbholz, Andi and Schmid-Ott, Ruprecht and Liese, Johannes G.},
  title     = {Similar severity of influenza primary and re-infections in pre-school children requiring outpatient treatment due to febrile acute respiratory illness: prospective, multicentre surveillance study (2013-2015)},
  series = {BMC Infectious Diseases},
  volume    = {22},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/s12879-021-06988-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265841},
  year      = {2022},
  abstract  = {Background Influenza virus infections in immunologically na{\"i}ve children (primary infection) may be more severe than in children with re-infections who are already immunologically primed. We compared frequency and severity of influenza virus primary and re-infections in pre-school children requiring outpatient treatment. Methods Influenza-unvaccinated children 1-5 years of age presenting at pediatric practices with febrile acute respiratory infection < 48 h after symptom onset were enrolled in a prospective, cross-sectional, multicenter surveillance study (2013-2015). Influenza types/subtypes were PCR-confirmed from oropharyngeal swabs. Influenza type/subtype-specific IgG antibodies serving as surrogate markers for immunological priming were determined using ELISA/hemagglutination inhibition assays. The acute influenza disease was defined as primary infection/re-infection by the absence/presence of influenza type-specific immunoglobulin G (IgG) and, in a second approach, by the absence/presence of subtype-specific IgG. Socio-demographic and clinical data were also recorded. Results Of 217 influenza infections, 178 were due to influenza A (87 [49\%] primary infections, 91 [51\%] re-infections) and 39 were due to influenza B (38 [97\%] primary infections, one [3\%] re-infection). Children with "influenza A primary infections" showed fever with respiratory symptoms for a shorter period than children with "influenza A re-infections" (median 3 vs. 4 days; age-adjusted p = 0.03); other disease characteristics were similar. If primary infections and re-infections were defined based on influenza A subtypes, 122 (87\%) primary infections (78 "A(H3N2) primary infections", 44 "A(H1N1)pdm09 primary infections") and 18 (13\%) re-infections could be classified (14 "A(H3N2) re-infections" and 4 "A(H1N1)pdm09 re-infections"). Per subtype, primary infections and re-infections were of similar disease severity. Children with re-infections defined on the subtype level usually had non-protective IgG titers against the subtype of their acute infection (16 of 18; 89\%). Some patients infected by one of the influenza A subtypes showed protective IgG titers (≥ 1:40) against the other influenza A subtype (32/140; 23\%). Conclusions Pre-school children with acute influenza A primary infections and re-infections presented with similar frequency in pediatric practices. Contrary to expectation, severity of acute "influenza A primary infections" and "influenza A re-infections" were similar. Most "influenza A re-infections" defined on the type level turned out to be primary infections when defined based on the subtype. On the subtype level, re-infections were rare and of similar disease severity as primary infections of the same subtype. Subtype level re-infections were usually associated with low IgG levels for the specific subtype of the acute infection, suggesting only short-time humoral immunity induced by previous infection by this subtype. Overall, the results indicated recurring influenza virus infections in this age group and no or only limited heterosubtypic antibody-mediated cross-protection.},
  language  = {en}
}
@article{StrengPrifertWeissbrichetal.2015,
  author    = {Streng, Andrea and Prifert, Christiane and Weissbrich, Benedikt and Liese, Johannes G.},
  title     = {Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11-2012/13},
  series = {BMC Infectious Diseases},
  volume    = {15},
  journal   = {BMC Infectious Diseases},
  number    = {573},
  organization    = {Bavarian PICU Study Group on Influenza and Other Viral ARI},
  doi       = {10.1186/s12879-015-1293-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125280},
  year      = {2015},
  abstract  = {Background Previous influenza surveillance at paediatric intensive care units (PICUs) in Germany indicated increased incidence of PICU admissions for the pandemic influenza subtype A(H1N1)pdm09. We investigated incidence and clinical characteristics of influenza in children admitted to PICUs during the first three post-pandemic influenza seasons, using active screening. Methods We conducted a prospective surveillance study in 24 PICUs in Bavaria (Germany) from October 2010 to September 2013. Influenza cases among children between 1 month and 16 years of age admitted to these PICUs with acute respiratory infection were confirmed by PCR analysis of respiratory secretions. Results A total of 24/7/20 influenza-associated PICU admissions were recorded in the post-pandemic seasons 1/2/3; incidence estimates per 100,000 children were 1.72/0.76/1.80, respectively. Of all 51 patients, 80 \% had influenza A, including 65 \% with A(H1N1)pdm09. Influenza A(H1N1)pdm09 was almost absent in season 2 (incidence 0.11), but dominated PICU admissions in seasons 1 (incidence 1.35) and 3 (incidence 1.17). Clinical data was available for 47 influenza patients; median age was 4.8 years (IQR 1.6-11.0). The most frequent diagnoses were influenza-associated pneumonia (62 \%), bronchitis/bronchiolitis (32 \%), secondary bacterial pneumonia (26 \%), and ARDS (21 \%). Thirty-six patients (77 \%) had underlying medical conditions. Median duration of PICU stay was 3 days (IQR 1-11). Forty-seven per cent of patients received mechanical ventilation, and one patient (2 \%) extracorporeal membrane oxygenation; 19 \% were treated with oseltamivir. Five children (11 \%) had pulmonary sequelae. Five children (11 \%) died; all had underlying chronic conditions and were infected with A(H1N1)pdm09. In season 3, patients with A(H1N1)pdm09 were younger than in season 1 (p = 0.020), were diagnosed more often with bronchitis/bronchiolitis (p = 0.004), and were admitted to a PICU later after the onset of influenza symptoms (p = 0.041). Conclusions Active screening showed a continued high incidence of A(H1N1)pdm09-associated PICU admissions in the post-pandemic seasons 1 and 3, and indicated possible underestimation of incidence in previous German studies. The age shift of severe A(H1N1)pdm09 towards younger children may be explained by increasing immunity in the older paediatric population. The high proportion of patients with underlying chronic conditions indicates the importance of consistent implementation of the current influenza vaccination recommendations for risk groups in Germany.},
  language  = {en}
}
@article{StrengGroteLiese2011,
  author    = {Streng, Andrea and Grote, Veit and Liese, Johannes G.},
  title     = {Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-69120},
  year      = {2011},
  abstract  = {Background: Data on complications in children with seasonal influenza virus infection are limited. We initiated a nation-wide three-year surveillance of children who were admitted to a paediatric intensive care unit (PICU) with severe seasonal influenza. Methods: From October 2005 to July 2008, active surveillance was performed using an established reporting system for rare diseases (ESPED) including all paediatric hospitals in Germany. Cases to be reported were hospitalized children < 17 years of age with laboratory-confirmed influenza treated in a PICU or dying in hospital. Results: Twenty severe influenza-associated cases were reported from 14 PICUs during three pre-pandemic influenza seasons (2005-2008). The median age of the patients (12 males/8 females) was 7.5 years (range 0.1-15 years). None had received vaccination against influenza. In 14 (70\%) patients, the infection had been caused by influenza A and in five (25\%) by influenza B; in one child (5\%) the influenza type was not reported. Patients spent a median of 19 (IQR 12-38) days in the hospital and a median of 11 days (IQR 6-18 days) in the PICU; 10 (50\%) needed mechanical ventilation. Most frequent diagnoses were influenza-associated pneumonia (60\%), bronchitis / bronchiolitis (30\%), encephalitis / encephalopathy (25\%), secondary bacterial pneumonia (25\%), and ARDS (25\%). Eleven (55\%) children had chronic underlying medical conditions, including 8 (40\%) with chronic pulmonary diseases. Two influenza A- associated deaths were reported: i) an 8-year old boy with pneumococcal encephalopathy following influenza infection died from cerebral edema, ii) a 14-year-old boy with asthma bronchiale, cardiac malformation and Addison's disease died from cardiac and respiratory failure. For nine (45\%) patients, possibly permanent sequelae were reported (3 neurological, 3 pulmonary, 3 other sequelae). Conclusions: Influenza-associated pneumonia and secondary bacterial infections are relevant complications of seasonal influenza in Germany. The incidence of severe influenza cases in PICUs was relatively low. This may be either due to the weak to moderate seasonal influenza activity during the years 2005 to 2008 or due to underdiagnosis of influenza by physicians. Fifty \% of the observed severe cases might have been prevented by following the recommendations for vaccination of risk groups in Germany.},
  subject      = {Deutschland},
  language  = {en}
}
@article{StrengGroteCarretal.2013,
  author    = {Streng, Andrea and Grote, Veit and Carr, David and Hagemann, Christine and Liese, Johannes G.},
  title     = {Varicella routine vaccination and the effects on varicella epidemiology - results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011},
  series = {BMC Infectious Diseases},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/1471-2334-13-303},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96297},
  year      = {2013},
  abstract  = {Background In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated. Methods Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated. Results Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38\%, 51\%, 53\%, 53\%, 66\% and 68\%); second-dose coverage reached 59\% in the 2011 survey. A monthly mean of 82 (62\%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67\% in two steps, from 6.6 (95\%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95\%CI 3.9-4.6) in 2007/08 and 4.0 (95\%CI 3.6-4.3) in 2008/09, and further to 2.3 (95\%CI 2.0-2.6) in 2009/10 and 2.2 (95\%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95\%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95\%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95\%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5\%) with neurological complications and one (0.6\%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age. Conclusions Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage.},
  language  = {en}
}
@article{StrengGoettlerHaerleinetal.2019,
  author    = {Streng, Andrea and Goettler, David and Haerlein, Miriam and Lehmann, Lisa and Ulrich, Kristina and Prifert, Christiane and Krempl, Christine and Weißbrich, Benedikt and Liese, Johannes G.},
  title     = {Spread and clinical severity of respiratory syncytial virus A genotype ON1 in Germany, 2011-2017},
  series = {BMC Infectious Diseases},
  volume    = {19},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/s12879-019-4266-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201516},
  pages     = {613},
  year      = {2019},
  abstract  = {Background The Respiratory Syncytial Virus (RSV) A genotype ON1, which was first detected in Ontario (Canada) in 2010/11, appeared in Germany in 2011/12. Preliminary observations suggested a higher clinical severity in children infected with this new genotype. We investigated spread and disease severity of RSV-A ON1 in pediatric in- and outpatient settings. Methods During 2010/11 to 2016/17, clinical characteristics and respiratory samples from children with acute respiratory tract infections (RTI) were obtained from ongoing surveillance studies in 33 pediatric practices (PP), one pediatric hospital ward (PW) and 23 pediatric intensive care units (PICU) in Germany. RSV was detected in the respiratory samples by PCR; genotypes were identified by sequencing. Within each setting, clinical severity markers were compared between RSV-A ON1 and RSV-A non-ON1 genotypes. Results A total of 603 children with RSV-RTI were included (132 children in PP, 288 in PW, and 183 in PICU). Of these children, 341 (56.6\%) were infected with RSV-A, 235 (39.0\%) with RSV-B, and one child (0.2\%) with both RSV-A and RSV-B; in 26 (4.3\%) children, the subtype could not be identified. In the 341 RSV-A positive samples, genotype ON1 was detected in 247 (72.4\%), NA1 in 92 (26.9\%), and GA5 in 2 children (0.6\%). RSV-A ON1, rarely observed in 2011/12, was the predominant RSV-A genotype in all settings by 2012/13 and remained predominant until 2016/17. Children in PP or PW infected with RSV-A ON1 did not show a more severe clinical course of disease compared with RSV-A non-ON1 infections. In the PICU group, hospital stay was one day longer (median 8 days, inter-quartile range (IQR) 7-12 vs. 7 days, IQR 5-9; p = 0.02) and duration of oxygen treatment two days longer (median 6 days, IQR 4-9 vs. 4 days, IQR 2-6; p = 0.03) for children infected with RSV-A ON1. Conclusions In children, RSV-A ON1 largely replaced RSV-A non-ON1 genotypes within two seasons and remained the predominant RSV-A genotype in Germany during subsequent seasons. A higher clinical severity of RSV-A ON1 was observed within the group of children receiving PICU treatment, whereas in other settings clinical severity of RSV-A ON1 and non-ON1 genotypes was largely similar.},
  language  = {en}
}
@article{PrifertStrengKrempletal.2013,
  author    = {Prifert, Christiane and Streng, Andrea and Krempl, Christine D. and Liese, Johannes and Weissbrich, Benedikt},
  title     = {Novel Respiratory Syncytial Virus A Genotype, Germany, 2011-2012},
  series = {Emerging Infectious Diseases},
  volume    = {19},
  journal   = {Emerging Infectious Diseases},
  number    = {6},
  doi       = {10.3201/eid1906.121582},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-129041},
  pages     = {1029-1030},
  year      = {2013},
  abstract  = {No abstract available.},
  language  = {en}
}
@article{PrelogZlamyKofleretal.2013,
  author    = {Prelog, Martina and Zlamy, Manuela and Kofler, Sabine and Orth, Dorothea and W{\"u}rzner, Reinhard and Heinz-Erian, Peter and Streng, Andrea},
  title     = {The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections},
  series = {BMC Infectious Diseases},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/1471-2334-13-112},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96147},
  year      = {2013},
  abstract  = {Background The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). Methods The retrospective evaluation (2002-2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002-2005) was compared with the recommended and early funded (2006-2007) and the funded (2008-2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons. Results In 1,532 children with RV-GE, a significant reduction by 73.9\% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0-11 months (by 87.8\%), 6-10 years (by 84.2\%) and 11-18 years (88.9\%). In the funded vaccination period, a reduction by 71.9\% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7\% in the funded vaccination period. The reduction of direct costs for patients (by 86.9\%) and accompanying persons (86.2\%) was most pronounced in the age group 0-11 months. Conclusions UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.},
  language  = {en}
}
@article{HagemannStrengKraemeretal.2017,
  author    = {Hagemann, Christine and Streng, Andrea and Kraemer, Alexander and Liese, Johannes G.},
  title     = {Heterogeneity in coverage for measles and varicella vaccination in toddlers - analysis of factors influencing parental acceptance},
  series = {BMC Public Health},
  volume    = {17},
  journal   = {BMC Public Health},
  number    = {724},
  doi       = {10.1186/s12889-017-4725-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157827},
  year      = {2017},
  abstract  = {Background: In 2004, routine varicella vaccination was introduced in Germany for children aged 11-14 months. Routine measles vaccination had already been introduced in 1973 for the same age group, but coverage is still too low (<95\%) in some areas to eliminate measles. The present study assessed varicella and measles vaccination coverage and determinants of parental acceptance in two study regions, situated in Northern and Southern Bavaria (Germany). Methods: From 2009 to 2011, annual cross-sectional parent surveys were performed on random samples of 600 children aged 18-36 months in the Bavarian regions of both Munich and W{\"u}rzburg. Logistic regression models were used to identify factors associated with varicella and measles vaccination. Results: In 2009, 2010 and 2011, vaccination coverage was lower in Munich than in W{\"u}rzburg, for both varicella (Munich 53\%, 67\%, 69\% vs. W{\"u}rzburg 72\%, 81\%, 83\%) and for measles (Munich 88\%, 89\%, 91\% vs. W{\"u}rzburg 92\%, 93\%, 95\%). Recommendation by the physician was the main independent factor associated with varicella vaccination in both regions (adjusted odd ratios (OR) with 95\% confidence interval (CI): Munich OR 19.7, CI 13.6-28.6; W{\"u}rzburg OR 34.7, CI 22.6-53.2). Attendance at a childcare unit was positively associated with a higher acceptance of varicella vaccination in Munich (OR 1.5, CI 1.1-2.2). Regarding measles vaccination, attendance at a childcare unit was positively associated in both regions (Munich OR 2.0; CI 1.3-3.0; W{\"u}rzburg OR 1.8; CI 1.1-3.1), and a higher level of parental school education was negatively associated in W{\"u}rzburg (OR 0.5, CI 0.3-0.9). Conclusions: Vaccination rates differed between regions, with rates constantly higher in W{\"u}rzburg. Within each region, vaccination rates were lower for varicella than for measles. Measles vaccination status was mainly dependent upon socio-demographic factors (attendance at a childcare unit, parental school education), whereas for the more recently introduced varicella vaccination recommendation by the physician had the strongest impact. Hence, different strategies are needed to further improve vaccination rates for both diseases.},
  language  = {en}
}